The DOI matches its Crossref record; 162 of the 162 references it cites were found in a registry or an index; 1 of the 43 sources its claims cite were checked for support.
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Open accessAbstract
Our objective was to update the EULAR recommendations for the management of systemic lupus erythematosus (SLE), based on emerging new evidence. We performed a systematic literature review (01/2007–12/2017), followed by modified Delphi method, to form questions, elicit expert opinions and reach consensus. Treatment in SLE aims at remission or low disease activity and prevention of flares. Hydroxychloroquine is recommended in all patients with lupus, at a dose not exceeding 5 mg/kg real body weight. During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn. Appropriate initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite the tapering/discontinuation of GC. In persistently active or flaring extrarenal disease, add-on belimumab should be considered; rituximab (RTX) may be considered in organ-threatening, refractory disease. Updated specific recommendations are also provided for cutaneous, neuropsychiatric, haematological and renal disease. Patients with SLE should be assessed for their antiphospholipid antibody status, infectious and cardiovascular diseases risk profile and preventative strategies be tailored accordingly. The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
This 2019 EULAR update provides consensus recommendations for managing systemic lupus erythematosus (SLE), based on a systematic literature review (2007–2017) and a Delphi process, yielding 33 final statements across goals of treatment, treatment, specific manifestations, and comorbidities. It emphasizes remission or low disease activity, hydroxychloroquine for all patients at ≤5 mg/kg real body weight, glucocorticoid minimization to <7.5 mg/day prednisone equivalent when possible, and add-on belimumab or rituximab in defined refractory settings.
Key findings
- The Task Force reached consensus on 33 final statements; treatment should aim at remission or low disease activity and prevention of flares. Hydroxychloroquine (HCQ) is recommended for all patients with SLE unless contraindicated, at a dose not exceeding 5 mg/kg real body weight, with ophthalmological screening at baseline, after 5 years, and yearly thereafter in the absence of retinal toxicity risk factors.
- For chronic maintenance, glucocorticoids should be minimized to less than 7.5 mg/day prednisone equivalent and withdrawn when possible; prompt initiation of immunomodulatory agents (methotrexate, azathioprine, mycophenolate) can expedite tapering/discontinuation. Add-on belimumab should be considered in extrarenal disease with inadequate response to standard care, and rituximab may be considered in organ-threatening, refractory disease.
- In lupus nephritis, mycophenolate or low-dose intravenous cyclophosphamide are recommended for induction, and mycophenolate or azathioprine for maintenance; high-dose intravenous cyclophosphamide can also be used in patients at high risk for renal failure. Calcineurin inhibitors may be considered as second-line agents mainly in membranous lupus nephritis, podocytopathy, or refractory nephrotic syndrome.
- All patients with SLE should be screened at diagnosis for antiphospholipid antibodies; infection and cardiovascular disease risk should be assessed and preventative strategies tailored. Low-dose aspirin may be considered for primary cardiovascular prevention (HR 0.24 in one retrospective study), but this must be balanced against bleeding hazard; routine statins are not recommended for all patients.
Methods
- After EULAR Executive Committee approval, a Task Force performed an update using EULAR standardised operating procedures and AGREE II. A systematic literature review screened PubMed for English-language publications from 01/2007 to 12/2017, with two exceptions: skin disease had an unrestricted date search, and renal disease was limited to 01/2012–12/2017.
- Fourteen research questions were selected via Delphi methodology; pertinent articles from manual reference-list searches were also included. Evidence was categorised by study design and validity, statements were graded, and after discussion rounds the committee reached consensus on 33 final statements, with each Task Force member rating agreement.
Limitations
- The paper states several evidence gaps: data on optimal duration and timing of therapy discontinuation in renal and extrarenal disease are scarce; calcineurin inhibitor studies in lupus nephritis were performed almost exclusively in Asian populations and had short follow-up; no studies have been performed exclusively in patients with SLE-antiphospholipid syndrome; and no formal studies address low-molecular-weight heparin during high-risk periods. It also notes that HCQ efficacy was established at 6.5 mg/kg/day, so whether a lower dose has comparable clinical effects remains to be confirmed, and data are insufficient to recommend routine drug-level monitoring.
- Evident from the text: the recommendations combine evidence and expert opinion, with many statements supported by low evidence grades (e.g., 4/C, 2b/C) and consensus agreement rather than high-quality randomized evidence. The systematic review ended in 12/2017, so later evidence is not incorporated.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
44 Not checked yet · 6 Own interpretation · 5 Own method · 1 Partly supported · accuracy not yet measured
In the paper
“In monitoring renal response, reduction of UPr (to less than 0.8 g/day) following treatment is more important than residual haematuria.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Goals of treatment
What the sources say
- Not checked yetcites [21] Dall'Era, 2015, Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus nephritis cohort, Arthritis Rheumatol source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“a prevalence of retinal abnormalities exceeding 10% after 20 years of continuous use.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Treatment of SLE Hydroxychloroquine
What the sources say
- Not checked yetcites 36 37
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Complete remission (absence of clinical activity with no use of GC and IS drugs) is infrequent.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Goals of treatment
What the sources say
- Not checked yetcites [12][13][14][15][16]
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“newly defined low disease activity states (based on a SLEDAI score ≤3 on antimalarials, or alternatively SLEDAI ≤4, PGA≤1 with GC ≤7.5 mg of prednisone and well tolerated IS agents) have shown comparable rates with remission, regarding halting of damage accrual (OR 0.5-0.7 for increase in damage index) and prevention of flares.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Goals of treatment
What the sources say
- Not checked yetcites 14 17-20
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“a posthoc analysis of the LUNAR trial showed that complete B-cell depletion following RTX treatment in LN was associated with higher odds for complete response at 78 weeks.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Biological agents
What the sources say
- Not checked yetcites [78] Gomez Mendez, 2018, Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis, Clin J Am Soc Nephrol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Published data support the use of MMF and high-dose CYC (online supplementary table 5) in severe forms of LN associated with increased risk of progression into end-stage renal disease”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Renal disease
What the sources say
- Not checked yetcites 118 119
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Drug blood levels can be used to assess compliance”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Treatment of SLE Hydroxychloroquine
What the sources say
- Not checked yetcites 33 35
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“longterm GC therapy can have various detrimental effects including irreversible organ damage.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Glucocorticoids
What the sources say
- Not checked yetcites [38][39][40][41]
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Consistently reported risk factors for a higher disease flare rate include younger age at disease onset, no use of antimalarials, persistent generalised disease activity and serological activity (anti-dsDNA, low complement).”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Goals of treatment
What the sources say
- Not checked yetcites [27][28][29][30][31]
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Concomitant use of GnRH analogues attenuates the depletion of ovarian reserve associated with CYC therapy”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Immunosuppressive (IS) drugs
What the sources say
- Not checked yetcites 4 58 59
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 9
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Treatment of thrombocytopenia is typically lengthy and often characterised by relapses during GC tapering.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Haematological disease
What the sources say
- Partly supportedcites [109] Jung, 2016, Thrombocytopenia in systemic lupus erythematosus: clinical manifestations, treatment, and prognosis in 230 patients, Medicine sourceExperimental — accuracy not yet measured
The Results report relapses in patients with SLE-associated thrombocytopenia, and the Discussion says some patients require continuous moderate doses of glucocorticoids. Neither section establishes that treatment is typically lengthy or that relapses occur specifically during glucocorticoid tapering. Page numbers are unavailable in our copy. (LLM, conf=0.84)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
In the paper
“Risks are substantially increased at continuous GC doses above 7.5 mg/day, with some studies suggesting that also lower doses might be harmful.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Glucocorticoids
What the sources say
- Not checked yetcites 17 42-44
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Consequent initiation of IS drugs facilitates a more rapid GC tapering and may prevent disease flares.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Immunosuppressive (IS) drugs
What the sources say
- Not checked yetcites [49] Pego-Reigosa, 2013, Efficacy and safety of nonbiologic immunosuppressants in the treatment of nonrenal systemic lupus erythematosus: a systematic review, Arthritis Care Res source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Distinction between the two pathophysiological processes may not be easy in clinical practice, or the two processes may coexist in the same patient.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Neuropsychiatric disease (NPSLE)
What the sources say
- Not checked yetcites [2] Bertsias, 2010, EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task Force of the EULAR standing Committee for clinical Affairs, Ann Rheum Dis source
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“low-dose CYC (Euro-Lupus regimen, online supplementary table 5) is preferred over highdose CYC as it has comparable efficacy and lower risk of gonadotoxicity.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Renal disease
What the sources say
- Not checked yetcites 57 116 117
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These studies were performed almost exclusively in Asian populations and had short follow-up; hence, data have to be corroborated with longer duration studies in multiethnic populations.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Renal disease
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Each Task Force member rated their agreement with each statement.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > MeTHods
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“the SLR considered all English-language publi- cations from 01/2007 until 12/2017, with two exceptions: (1) treatment of skin disease, where an unrestricted date search was performed and (2) renal disease, where search was limited to the period 01/2012-12/2017”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > MeTHods
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Patients with more severe proteinuria and longerstanding disease are less likely to respond or show more delayed responses.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Goals of treatment
What the sources say
- Not checked yetcites 22 23
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“RTX has demonstrated efficacy both in lupus and in patients with isolated immune thrombocytopaenia (ITP).”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Biological agents
What the sources say
- Not checked yetcites [74][75]5][76]
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“it remains to be confirmed whether a lower dose will have comparable clinical effects.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Treatment of SLE Hydroxychloroquine
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Major risk factors for retinopathy include duration of treatment (OR 4.71 for every 5 years of use), dose (OR 3.34 for every 100 mg daily dose), chronic kidney disease (adjusted OR 8.56) and pre-existing retinal or macular disease.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Treatment of SLE Hydroxychloroquine
What the sources say
- Not checked yetcites [37] Kim, 2017, Risk of retinal toxicity in longterm users of hydroxychloroquine, J Rheumatol source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Mycophenolate mofetil (MMF) is a potent immunosuppressant with efficacy in renal and non-renal lupus (although not in neuropsychiatric disease).”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Immunosuppressive (IS) drugs
What the sources say
- Not checked yetcites [51][52][53]
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Belimumab and RTX have also shown efficacy in mucocutaneous manifestations of SLE, although these studies have not included a validated activity score for skin lesions”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Skin disease
What the sources say
- Not checked yetcites 62 92-94
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Treatment of NPSLE depends on whether the underlying pathophysiological mechanism is presumed to be inflammatory or embolic/thrombotic/ischaemic.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Neuropsychiatric disease (NPSLE)
What the sources say
- Not checked yetcites 2 101
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Flares are common in the disease course and contribute significantly to organ damage accrual and worse outcome.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Goals of treatment
What the sources say
- Not checked yetcites 17 25 26
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The EULAR standardised operating procedures 7 and the Appraisal of Guidelines Research and Evaluation instrument (AGREE II) 8 were followed.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > MeTHods
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Applying a Delphi-based methodology, 14 research questions were selected for SLR (online supplementary table 1).”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > MeTHods
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There are no studies examining retinal toxicity of quinacrine with the newer, more sensitive screening techniques (visual fields or optical coherence tomography); however with current knowledge, retinopathy is not considered a side-effect of quinacrine.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Skin disease
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“MMF or AZA may be used as maintenance therapy, with the former associated with fewer relapses”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Renal disease
What the sources say
- Not checked yetcites 121 122
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Patients with persistent disease may benefit from belimumab; more likely to respond are patients with high disease activity (eg, SLEDAI >10), prednisone dose >7.5 mg/day and serological activity (low C3/C4, high anti-dsDNA titres), with cutaneous, musculoskeletal and serological manifestations responding the most.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Biological agents
What the sources say
- Not checked yetcites [67][68][69]
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“After rounds of discussions, the committee reached a consensus of 33 final statements, grouped in four broad categories”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > MeTHods
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“it is not clear whether this should be applied to patients with lupus with any aPL antibodies or only to those carrying a high risk aPL profile”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“SLE is an independent risk factor for cardiovascular disease (CVD), due to both traditional and disease-related risk factors, such as persistent disease activity, LN, presence of aPL and use of GC.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Cardiovascular disease
What the sources say
- Not checked yetcites [147][148][149]
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“recent studies support the value of a repeat kidney biopsy for the management of maintenance therapy, but more data are needed.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Cardiovascular disease
What the sources say
- Not checked yetcites 158 159
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No studies have been performed exclusively on patients with SLE-APS, with several studies excluding secondary APS due to lupus.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Risk of infection in SLE is associated with both disease-related and treatment-related factors; high-dose GC therapy, CYC, MMF and RTX are all associated with an increased risk for infection, while high disease activity, severe leucopaenia and presence of renal involvement (±hypogammaglobulinaemia in nephrotic syndrome) also contribute independently.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Infections
What the sources say
- Not checked yetcites 48 140-143
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The presence of aPL is associated with thrombotic and obstetric complications and increased risk of damage accrual.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Antiphospholipid antibodies (aPL) and antiphospholipid syndrome (APS)
What the sources say
- Not checked yetcites 133 134
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
The evidence from studies in patients with cutaneous lupus erythematosus applies to skin disease in SLE.
“A large body of evidence originates from studies in patients with cutaneous lupus erythematosus (CLE).”
The paper relies on this without support.
The bleeding hazard from aspirin observed in diabetics and elderly applies to patients with SLE.
“However, this has to be viewed in light of recent large studies in diabetics and elderly showing that the benefits of aspirin for primary CVD prevention are counterbalanced by the larger bleeding hazard.”
The paper relies on this without support.
The results of the rivaroxaban versus warfarin trial in APS with triple antiphospholipid positivity apply to patients with SLE-APS.
“A recent randomised, open-label trial comparing rivaroxaban to warfarin in APS with triple aPL positivity (~21% of patients had SLE-APS) was prematurely terminated due to an excess of thromboembolic events in the rivaroxaban arm.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Due to the negative results of randomized, controlled trials (RCTs), RTX is currently only used off-label, in patients with severe renal or extrarenal (mainly hematological and neuropsychiatric) disease refractory to other IS agents and/or BLM, or in patients with contraindications to these drugs.73”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Abstract
“During chronic maintenance treatment, glucocorticoids (GC) should be minimised to less than 7.5 mg/day (prednisone equivalent) and, when possible, withdrawn.”
§ 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus > Glucocorticoids
“GC can provide rapid symptom relief, but the medium to longterm aim should be to minimise daily dose to ≤7.5 mg/day prednisone equivalent or to discontinue them”
Citations
Cites
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Seymour, C. W., Liu, V. X., Iwashyna, T. J., Brunkhorst, F. M., Rea, T. D., Scherag, A., Rubenfeld, G., Kahn, J. M., Shankar-Hari, M., Singer, M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0288 · Cited by 3,939
AGREE II: advancing guideline development, reporting and evaluation in health care
Brouwers, M. C., Kho, M. E., Browman, G. P., Burgers, J. S., Cluzeau, F., Feder, G., Fervers, B., Graham, I. D., Grimshaw, J., Hanna, S. E., et al. (2010) · Canadian Medical Association Journal · doi:10.1503/cmaj.090449 · Cited by 3,790
Navarra, S., Guzmán, R., Gallacher, A., Hall, S., Levy, R. A., Jimenez, R., Li, E. K., Thomas, M., Kim, H., Leon, M. G., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61354-2 · Cited by 2,078
Furie, R. A., Petri, M., Zamani, O., Cervera, R., Wallace, D. J., Tegzová, D., Sánchez‐Guerrero, J., Schwarting, A., Merrill, J. T., Chatham, W. W., et al. (2011) · Arthritis & Rheumatism · doi:10.1002/art.30613 · Cited by 1,687
Self-citationRovin, B. H., Furie, R. A., Latinis, K. M., Looney, R. J., Fervenza, F. C., Sánchez‐Guerrero, J., Maciuca, R. D., Zhang, D., Garg, J. P., Brunetta, P. G., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,507
Merrill, J. T., Neuwelt, C. M., Wallace, D. J., Shanahan, J. C., Latinis, K. M., Oates, J. C., Utset, T. O., Gordon, C., Isenberg, D. A., Hsieh, H., et al. (2009) · Arthritis & Rheumatism · doi:10.1002/art.27233 · Cited by 1,442
Self-citationEffects of aspirin for primary prevention in persons with diabetes mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804988 · Cited by 1,200
Houssiau, F., Vasconcelos, C., D’Cruz, D. P., Sebastiani, G. D., Garrido, E. D. R., Danieli, M. G., Abramowicz, D., Blockmans, D., Mathieu, A., Di̇reskeneli̇, H., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10461 · Cited by 1,074
Self-citation
Cited by
Sorted by citations
Items 201–300 of 1,001
Tumor necrosis factor-α inhibitor-related autoimmune disorders
Stefano, L. D., Bobbio‐Pallavicini, F., Mauric, E., Piccin, V., Vismara, E. M., Montecucco, C., & Bugatti, S. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103332 · Cited by 41
Revisited Cyclophosphamide in the Treatment of Lupus Nephritis
Quan, X.-Y., Chen, H.-T., Liang, S.-Q., Yang, C., Yao, C., Xu, Y., Liu, H.-F., & An, N. (2022) · BioMed Research International · doi:10.1155/2022/8345737 · Cited by 40
Artemisinins: Promising drug candidates for the treatment of autoimmune diseases
Gao, X., Lin, X., Wang, Q., & Chen, J. (2023) · Medicinal Research Reviews · doi:10.1002/med.22001 · Cited by 40
Predictors of predominant Lupus Low Disease Activity State (LLDAS-50)
Babaoğlu, H., Li, J., GOLDMAN, D. W., Magder, L. S., & Petri, M. (2019) · Lupus · doi:10.1177/0961203319886028 · Cited by 40
Jin, W., Luo, Z., & Yang, H. (2020) · Journal of Immunology Research · doi:10.1155/2020/9518137 · Cited by 40
Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients
Salazar‐Camarena, D. C., Palafox‐Sánchez, C. A., Cruz, Á., Marín‐Rosales, M., & Muñóz-Valle, J. F. (2020) · Scientific Reports · doi:10.1038/s41598-020-63390-0 · Cited by 40
Coronavirus disease 2019 (COVID-19) and autoimmunity
Nasonov, E. L. (2021) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2021-5-30 · Cited by 41
Fasano, S., Coscia, M. A., Pierro, L., & Ciccia, F. (2021) · Lupus · doi:10.1177/09612033211002269 · Cited by 40
Roussotte, M., Gerfaud‐Valentin, M., Hot, A., Audia, S., Bonnotte, B., Thibault, T., Lobbes, H., Guenno, G. L., Goulabchand, R., Cathébras, P. J., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/keab925 · Cited by 40
Systemic lupus erythematosus – Are children miniature adults?
Alexander, T., & Hedrich, C. M. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108907 · Cited by 41
Haugaard, J. H., Dreyer, L., Ottosen, M. B., Gislason, G., Kofoed, K., & Egeberg, A. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.12.013 · Cited by 39
Autophagy in lupus nephritis: A delicate balance between regulation and disease
Podestà, M. A., Faravelli, I., & Ponticelli, C. E. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103132 · Cited by 39
Application of Machine Learning Models in Systemic Lupus Erythematosus
Ceccarelli, F., Natalucci, F., Picciariello, L., Ciancarella, C., Dolcini, G., Gattamelata, A., Alessandri, C., & Conti, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24054514 · Cited by 42
Blüm, P., & Käyser, S. (2024) · Cancers · doi:10.3390/cancers16081599 · Cited by 42
Li, C., Wu, F., Mao, J., Wang, Y., Zhu, J., Hong, K., Xie, H., Zhou, X., Tian, J., & Wen, C. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-03834-w · Cited by 39
Parodis, I., Lindblom, J., Levy, R. A., Zen, M., Çetrez, N., Gómez, A., Oon, S., Henning, C., Khamashta, M. A., Quasny, H., et al. (2024) · The Lancet Rheumatology · doi:10.1016/s2665-9913(24)00162-0 · Cited by 39
Cheerios Effect Inspired Microbubbles as Suspended and Adhered Oral Delivery Systems
Zhao, C., Cai, L., Nie, M., Shang, L., Wang, Y., & Zhao, Y. (2021) · Advanced Science · doi:10.1002/advs.202004184 · Cited by 39
Depascale, R., Frate, G. D., Gasparotto, M., Manfrè, V., Gatto, M., Iaccarino, L., Quartuccio, L., Vita, S. D., & Doria, A. (2021) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x211040696 · Cited by 39
Self-citationRituximab in the real-world treatment of lupus nephritis: A retrospective cohort study in Japan
Tanaka, Y., Nakayamada, S., Yamaoka, K., Ohmura, K., & Yasuda, S. (2022) · Modern Rheumatology · doi:10.1093/mr/roac007 · Cited by 39
Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus
Choi, M. Y., Guan, H., Yoshida, K., Paudel, M. L., Kargère, B., Li, D., Ellrodt, J., Stevens, E. F., Cai, T. A., Weber, B., et al. (2024) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2024.152468 · Cited by 38
Recurrent Pericarditis in Children and Adolescents
Tombetti, E., Giani, T., Brucato, A. L., & Cimaz, R. (2019) · Frontiers in Pediatrics · doi:10.3389/fped.2019.00419 · Cited by 39
Twelve-month outcome in juvenile proliferative lupus nephritis: results of the German registry study
Suhlrie, A., Hennies, I., Gellermann, J., Büscher, A. K., Hoyer, P. F., Waldegger, S., Wygoda, S., Beetz, R., Lange-Sperandio, B., Klaus, G., et al. (2020) · Pediatric Nephrology · doi:10.1007/s00467-020-04501-x · Cited by 38
Westermann, R., Zobbe, K., Cordtz, R., Haugaard, J. H., & Dreyer, L. (2021) · Lupus · doi:10.1177/0961203321990106 · Cited by 39
Yang, C., Wu, M., You, M., Chen, Y., Luo, M., & Chen, Q. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02158-3 · Cited by 40
Ji, L., Xie, W., Fasano, S., & Zhang, Z. (2022) · Lupus Science & Medicine · doi:10.1136/lupus-2021-000603 · Cited by 38
Huang, S. P., Snedecor, S. J., Nanji, S., Lloyd, E., & Bell, C. F. (2022) · Rheumatology and Therapy · doi:10.1007/s40744-022-00454-9 · Cited by 38
What do clinical practice guidelines say about deprescribing? A scoping review
Langford, A. V., Warriach, I., McEvoy, A. M., Karaim, E., Chand, S., Turner, J. P., Thompson, W., Farrell, B. J., Pollock, D., Moriarty, F., et al. (2024) · BMJ Quality & Safety · doi:10.1136/bmjqs-2024-017101 · Cited by 37
Binda, V., Trezzi, B., Papa, N. D., Beretta, L., Frontini, G., Porata, G., Fabbrini, P., Pozzi, M. R., Messa, P., Sinico, R. A., et al. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00706-3 · Cited by 37
Self-citationParodis, I., Åkerström, E., Sjöwall, C., Sohrabian, A., Jönsen, A., Gómez, A., Frodlund, M., Zickert, A., Bengtsson, A. A., Rönnelid, J., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103463 · Cited by 37
Martin, M., Trattner, R., Nilsson, S. C., Björk, A., Zickert, A., Blom, A. M., & Gunnarsson, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582737 · Cited by 37
Neuberger, E. W. I., Brahmer, A., Ehlert, T., Kluge, K., Philippi, K. F. A., Boedecker-Lips, S. C., Weinmann‐Menke, J., & Simon, P. D. (2021) · Scientific Reports · doi:10.1038/s41598-021-92826-4 · Cited by 37
Perspectives on Mycophenolate Mofetil in the Management of Autoimmunity
Bhat, R., Tonutti, A., Timilsina, S., Selmi, C. F., & Gershwin, M. E. (2023) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-023-08963-3 · Cited by 36
A comprehensive review on glucocorticoids induced osteoporosis: A medication caused disease
Rahman, A., & Haider, M. F. (2024) · Steroids · doi:10.1016/j.steroids.2024.109440 · Cited by 37
Towards Precision Medicine in Systemic Lupus Erythematosus
Lever, E., Alves, M. R., & Isenberg, D. A. (2020) · Pharmacogenomics and Personalized Medicine · doi:10.2147/pgpm.s205079 · Cited by 36
Chronic treatment with hydroxychloroquine and SARS‐CoV‐2 infection
Ferreira, A., Oliveira‐e‐Silva, A., & Bettencourt, P. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26286 · Cited by 36
Systemic lupus erythematosus: year in review 2019
Fan, Y., Hao, Y., & Zhang, Z. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000983 · Cited by 36
Sinh, P., & Cross, R. K. (2020) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izaa258 · Cited by 36
Reátegui-Sokolova, C., Ugarte-Gil, M. F., Harvey, G., WOJDYLA, D. M., Pons‐Estel, G., Quintana, R., Morales, R. M. S., Sacnun, M. P., Catoggio, L. J., Soriano, E. R., et al. (2020) · RMD Open · doi:10.1136/rmdopen-2020-001299 · Cited by 36
Piga, M., Floris, A., Congia, M., Chessa, E., Cangemi, I., & Cauli, A. (2021) · Rheumatology · doi:10.1093/rheumatology/keab632 · Cited by 36
Personalized Medicine and Machine Learning: A Roadmap for the Future
Sebastiani, M., Vacchi, C., Manfredi, A., & Cassone, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144110 · Cited by 36
Goodman, S. M., Springer, B. D., Chen, A. F., Davis, M., Fernández, D., Figgie, M. P., Finlayson, H., George, M., Giles, J. T., Gililland, J. M., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42140 · Cited by 35
Fasano, S., Messiniti, V., Iudici, M., Coscia, M. A., & Ciccia, F. (2023) · Lupus Science & Medicine · doi:10.1136/lupus-2022-000841 · Cited by 35
Targeting DORIS Remission and LLDAS in SLE: A Review
Sánchez, A. R. P., van Vollenhoven, R., Morand, E. F., Bruce, I. N., Kandane‐Rathnayake, R., Weiss, G., Tummala, R., Al‐Mossawi, H., & Sorrentino, A. (2023) · Rheumatology and Therapy · doi:10.1007/s40744-023-00601-w · Cited by 35
Tsoi, A., Gómez, A., Boström, C., Pezzella, D., Chow, J. W., Girard-Guyonvarc’h, C., Stamm, T., Arnaud, L., & Parodis, I. (2024) · Rheumatology International · doi:10.1007/s00296-024-05548-x · Cited by 35
Yin, X., Li, Q., Shu, Y., Wang, H., Thomas, B., Maxwell, J. T., & Zhang, Y. (2024) · Journal of Biomedical Science · doi:10.1186/s12929-024-01035-4 · Cited by 37
Thalidomide and Lenalidomide for Refractory Systemic/Cutaneous Lupus Erythematosus Treatment
Yuki, E. F. N., Silva, C. A., Aikawa, N. E., Romiti, R., Heise, C. O., Bonfá, E., & Pasoto, S. G. (2019) · JCR Journal of Clinical Rheumatology · doi:10.1097/rhu.0000000000001160 · Cited by 35
Umeda, R., Ogata, S., Hara, S., Takahashi, K., Inaguma, D., Hasegawa, M., Yasuoka, H., Yuzawa, Y., Hayashi, H., & Tsuboi, N. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02358-x · Cited by 35
Garantziotis, P., Nikolakis, D., Doumas, S., Frangou, E. A., Sentis, G., Filia, A., Fanouriakis, A., Bertsias, G. K., & Boumpas, D. T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.860726 · Cited by 34
Self-citationMitochondria in innate immunity signaling and its therapeutic implications in autoimmune diseases
Jiao, Y., Yan, Z., & Yang, A. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1160035 · Cited by 35
Novel and potential future therapeutic options in systemic autoimmune diseases
Balogh, L., Oláh, K., Sánta, S., Majerhoffer, N., & Németh, T. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1249500 · Cited by 36
Systemic lupus erythematosus in the intensive care unit: a systematic review
Suárez-Avellaneda, A., Quintana, J. H., Aragón, C. C., Gallego, L. M., Gallego, C.-N., Bolaños, J. D., Guerra, M. A., Ochoa, M. E., Granados, M., Ruíz-Ordóñez, I., et al. (2020) · Lupus · doi:10.1177/0961203320941941 · Cited by 34
Quality and best practice in medical laboratories: specific requests for autoimmunity testing
Sack, U., Bossuyt, X., Andreeva, H., Antal‐Szalmás, P., Bizzaro, N., Bogdanos, D. P., Borzova, E. Y., Conrad, K., Dragon‐Durey, M., Eriksson, C., et al. (2020) · Autoimmunity Highlights · doi:10.1186/s13317-020-00134-0 · Cited by 34
Yang, H., Liu, H., Zhou, Z., Zhao, L., Fei, Y., Chen, H., Zhang, F., & Zhang, X. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08817-2 · Cited by 34
Rafael‐Vidal, C., Altabás‐González, I., Pérez, N., Mouriño, C., Pego‐Reigosa, J. M., & García, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031263 · Cited by 34
Libman-Sacks endocarditis and associated cerebrovascular disease: The role of medical therapy
Roldan, C. A., Sibbitt, W. L., Greene, E. R., Qualls, C., & Jung, R. E. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247052 · Cited by 34
Ruiz‐Irastorza, G., Dueña-Bartolomé, L., Dunder, S., Varona, J., Gómez-Carballo, C., Dominguez-Cainzos, J., Rodrigo-Manjon, A., Bueno, L., Richez, C., Duffau, P., et al. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102898 · Cited by 34
Radin, M., Miraglia, P., Barinotti, A., Fenoglio, R., Roccatello, D., & Sciascia, S. (2021) · American Journal of Nephrology · doi:10.1159/000517852 · Cited by 34
Hammond, E. R., Desta, B., Near, A. M., Wang, X., & Jiang, M. (2021) · Lupus Science & Medicine · doi:10.1136/lupus-2021-000504 · Cited by 34
Organ damage in Systemic Lupus Erythematosus patients: A multifactorial phenomenon
Ceccarelli, F., Perricone, C., Natalucci, F., Picciariello, L., Olivieri, G., Cafaro, G., Bartoloni, E., Gerli, R., & Conti, F. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103374 · Cited by 34
Preeclampsia and the Antiphospholipid Syndrome
Mayer-Pickel, K. I., Nanda, M., Gajić, M., & Cervar-Zivkovic, M. (2023) · Biomedicines · doi:10.3390/biomedicines11082298 · Cited by 33
Update on the pathogenesis of central nervous system lupus
Nikolopoulos, D., Fanouriakis, A., & Boumpas, D. T. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000655 · Cited by 33
Self-citationTargeted Biologic Therapy for Systemic Lupus Erythematosus: Emerging Pathways and Drug Pipeline
Klavdianou, K., Lazarini, A., & Fanouriakis, A. (2020) · BioDrugs · doi:10.1007/s40259-020-00405-2 · Cited by 33
Self-citationPROSPECTS FOR ANTI-B-CELL THERAPY IN IMMUNO-INFLAMMATORY RHEUMATIC DISEASES
Nasonov, E. L., Beketova, T. V., Ananyeva, L. P., Vasilyev, V. I., Solovyev, S. K., & Avdeeva, A. S. (2019) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2019-3-40 · Cited by 33
A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus
Hanaoka, H., Nishimoto, T., Okazaki, Y., Takeuchi, T., & Kuwana, M. (2020) · Arthritis Research & Therapy · doi:10.1186/s13075-020-02183-2 · Cited by 34
Gao, D., Hao, Y., Mu, L., Xie, W., Fan, Y., Ji, L., & Zhang, Z. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa120 · Cited by 33
Update on antimalarials and systemic lupus erythematosus
Ruiz‐Irastorza, G., Martín‐Iglesias, D., & Soto-Peleteiro, A. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000743 · Cited by 33
Atienza‐Mateo, B., Remuzgo‐Martínez, S., Prieto-Pena, D., Cuesta, V. M. M., Fernandez, D. I., Llorca, J., Sánchez-Bilbao, L., Corrales, A., Rodríguez, G. B., Gómez‐Román, J., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103070 · Cited by 33
Brunner, H. I., Abud‐Mendoza, C., Mori, M., Pilkington, C., Syed, R. H., Takei, S., Viola, D. O., Furie, R. A., Navarra, S., Zhang, F., et al. (2021) · RMD Open · doi:10.1136/rmdopen-2021-001747 · Cited by 33
The Microbiota in Systemic Lupus Erythematosus: An Update on the Potential Function of Probiotics
Guo, X., Yang, X., Li, Q., Shen, X., Zhong, H., & Yang, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.759095 · Cited by 34
New developments in systemic lupus erythematosus
Tsang-A-Sjoe, M. W. P., & Bultink, I. E. M. (2021) · Rheumatology · doi:10.1093/rheumatology/keab498 · Cited by 33
Assunção, H., Jesús, D., Larosa, M., Henriques, C., Matos, A. C., Guern, V. L., Rubiño, F. J., da Silva, J. A. P., Rúa‐Figueroa, Í., Costedoat-Chalumeau, N., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/keab895 · Cited by 33
Self-citationHu, Z., Gao, R., Huang, W., Wang, H., & Qin, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12020485 · Cited by 33
Clinical aspects of cutaneous lupus erythematosus
Elmgren, J. K., & Nyberg, F. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.984229 · Cited by 32
Zen, M., Gatto, M., Depascale, R., Regola, F., Fredi, M., Andréoli, L., Franceschini, F., Urban, M. L., Emmi, G., Ceccarelli, F., et al. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13040691 · Cited by 32
Self-citationErosive arthritis in systemic lupus erythematosus: not only Rhupus
Ceccarelli, F., Natalucci, F., Olivieri, G., Perricone, C., Pirone, C., Spinelli, F. R., Alessandri, C., & Conti, F. (2021) · Lupus · doi:10.1177/09612033211051637 · Cited by 32
So, H., Li, T., Chan, V., Tam, L., & Chan, P. K. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221089586 · Cited by 33
Belimumab for systemic lupus erythematosus – Focus on lupus nephritis
Plüß, M., Piantoni, S., Tampe, B., Kim, A. H. J., & Korsten, P. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2072143 · Cited by 32
Shandil, R. K., Dhup, S., & Narayanan, S. (2022) · Stem Cells International · doi:10.1155/2022/6379161 · Cited by 32
Sagy, I., Zeller, L., Raviv, Y., Porges, T., Bieber, A., & Abu‐Shakra, M. (2022) · Rheumatology International · doi:10.1007/s00296-022-05203-3 · Cited by 32
Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?
Richter, P., Cardoneanu, A., Burlui, A., Macovei, L. A., Bratoiu, I., Buliga-Finiș, O. N., & Rezuş, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911788 · Cited by 33
Bruscoli, S., Puzzovio, P. G., Zaimi, M., Tiligada, K., Levi‐Schaffer, F., & Riccardi, C. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106511 · Cited by 34
B cell depletion and inhibition in systemic lupus erythematosus
Krustev, E., Clarke, A. E., & Barber, M. R. W. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2145281 · Cited by 32
Kneeland, R., Montes, D., Endo, J. O., Shields, B. E., Bartels, C. M., & Garg, S. (2022) · Arthritis Care & Research · doi:10.1002/acr.25058 · Cited by 32
Kojima, M., Suzuki, K., Takeshita, M., Ohyagi, M., Iizuka, M., Yamane, H., Koga, K., Kouro, T., Kassai, Y., Yoshihara, T., et al. (2023) · Communications Biology · doi:10.1038/s42003-023-04874-3 · Cited by 31
Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases
Lyu, X., Gupta, L., Tholouli, E., & Chinoy, H. (2023) · Rheumatology · doi:10.1093/rheumatology/kead616 · Cited by 34
Fang, H., Chen, L., & Knight, J. C. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30134-1 · Cited by 32
Treat-to-target in systemic lupus erythematosus: Where are we?
Garcés, R. R., Espinosa, G., van Vollenhoven, R., & Cervera, R. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.01.018 · Cited by 31
Self-citationAn Update on the Diagnosis and Management of Lupus Nephritis
Kostopoulou, M., Adamichou, C., & Bertsias, G. K. (2020) · Current Rheumatology Reports · doi:10.1007/s11926-020-00906-7 · Cited by 31
Self-citationWahezi, D. M., Lo, M. S., Rubinstein, T. B., Ringold, S., Ardoin, S. P., Downes, K. J., Jones, K. B., Laxer, R. M., Madan, R. P., Mudano, A. S., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41455 · Cited by 31
Yan, Q., Chen, W., Song, H. L., Long, X., Zhang, Z., Tang, X., Chen, H., He, L., & Sun, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.675542 · Cited by 31
Moreno‐Torres, V., Tarín, C., Ruiz‐Irastorza, G., Castejón, R., Gutiérrez‐Rojas, Á., Royuela, A., Campo, P. D., Mellor‐Pita, S., Tutor, P., Rosado, S., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10245749 · Cited by 31
Bruce, I. N., Golam, S. M., Steenkamp, J., Wang, P., Worthington, E., Desta, B., Psachoulia, K., Erhardt, W., & Tummala, R. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0040 · Cited by 31
Floris, A., Chessa, E., Sebastiani, G. D., Prevete, I., Iannone, F., Coladonato, L., Govoni, M., Bortoluzzi, A., Mosca, M., Tani, C., et al. (2022) · RMD Open · doi:10.1136/rmdopen-2022-002701 · Cited by 31
Self-citationMaterne, E., Choi, H. K., Zhou, B., Costenbader, K. H., Zhang, Y., & Jorge, A. M. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42620 · Cited by 31
Fanouriakis, A., Bertsias, G. K., & Boumpas, D. T. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217356 · Cited by 31
Self-citationRojo, R., Alén, J. C., Prada, A. J., Valor, S., Roy, G., López‐Hoyos, M., Cervera, R., Sánchez‐Mateos, P., & Jurado, A. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103479 · Cited by 30
Self-citationBellan, M., Patrucco, F., Barone‐Adesi, F., Gavelli, F., Castello, L. M., Nerviani, A., Andréoli, L., Cavagna, L., Pirisi, M., & Sainaghi, P. P. (2019) · Autoimmunity Reviews · doi:10.1016/j.autrev.2019.102453 · Cited by 30
Ajeganova, S., Gustafsson, T. P., Lindberg, L., Hafström, I., & Frostegård, J. (2020) · Lupus Science & Medicine · doi:10.1136/lupus-2019-000362 · Cited by 30
De novo lupus nephritis during treatment with belimumab
Parodis, I., Vital, E. M. J., Hassan, S.-U., Jönsen, A., Bengtsson, A. A., Eriksson, P., Leonard, D., Gunnarsson, I., Rönnblom, L., & Sjöwall, C. (2020) · Rheumatology · doi:10.1093/rheumatology/keaa796 · Cited by 30
Wade, S. D., & Kyttaris, V. C. (2021) · Rheumatology International · doi:10.1007/s00296-021-04847-x · Cited by 30
Metadata
- Authors
- Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., Houssiau, F., Jayne, D., Kouloumas, M., Kuhn, A., Larsen, J. L., Lerstrøm, K., Moroni, G., Mosca, M., Schneider, M., Smolen, J. S., Svenungsson, E., Tesar, V., Tincani, A., Troldborg, A., van Vollenhoven, R., Wenzel, J., Bertsias, G., & Boumpas, D. T.
- Affiliations
- University General Hospital Attikon (GR)
- General Hospital of Athens G. Genimatas (GR)
- University of Perugia (IT)
- University Hospital Carl Gustav Carus (DE)
- Leiden University Medical Center (NL)
- National and Kapodistrian University of Athens (GR)
- Hospital Clínic de Barcelona (ES)
- University of Padua (IT)
- University of Birmingham (GB)
- University of Ferrara (IT)
- Cliniques Universitaires Saint-Luc (BE)
- Addenbrooke's Hospital (GB)
- University Hospital Münster (DE)
- Rigshospitalet (DK)
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT)
- University of Pisa (IT)
- Heinrich Heine University Düsseldorf (DE)
- Medical University of Vienna (AT)
- Karolinska University Hospital (SE)
- Aarhus University Hospital (DK)
- University Hospital of Heraklion (GR)
- Corresponding author
- Fanouriakis, Antonis
- ORCID
- Fanouriakis, Antonis
- Kostopoulou, Myrto
- Alunno, Alessia
- Aringer, Martin
- Boletis, John N
- Cervera, Ricard
- Doria, Andrea
- Gordon, Caroline
- Govoni, Marcello
- Houssiau, Frédéric
- Jayne, David
- Kuhn, Annegret
- Moroni, Gabriella
- Mosca, Marta
- Schneider, Matthias
- Smolen, Josef S
- Svenungsson, Elisabet
- Troldborg, Anne
- Bertsias, George
- Boumpas, Dimitrios T
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 78
- Issue
- 6
- Pages
- 736-745
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2927871970
- Semantic Scholar
- 2a633e82de004894ad42e33a1bbbd71645ad7dd5
- Cited by
- 2,011
- References
- 162
- Citations by year
- 2026: 132 · 2025: 189 · 2024: 322 · 2023: 349 · 2022: 347 · 2021: 317 · 2020: 271 · 2019: 77
- FWCI
- 191.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Annals of the Rheumatic Diseases (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion, other-oa)
- Apollo (University of Cambridge) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
- Institutional Research Information System (Università degli Studi di Brescia) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion, other-oa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Apollo
- Funders
- European League Against Rheumatism
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › Vasculitis and related conditions
- Keywords
- systemic lupus erythematosus, lupus management, hydroxychloroquine, glucocorticoid tapering, immunomodulators, belimumab, rituximab, disease flares, cutaneous lupus erythematosus, neuropsychiatric lupus, renal lupus, antiphospholipid antibodies, cardiovascular risk, infectious disease risk, EULAR recommendations
- MeSH terms
- Biological Products, Glucocorticoids, Humans, Hydroxychloroquine, Immunosuppressive Agents, Lupus Erythematosus, Systemic, Severity of Illness Index, Comorbidity, Evidence-Based Medicine, Disease Management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-09, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-09 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
